Guidant COMPANION Results Support Contak CD Mortality Benefit
This article was originally published in The Gray Sheet
Executive Summary
Guidant's Contak CD cardiac resynchronization therapy pacemaker/ICD demonstrated a 40% reduction in all-cause mortality compared with optimum medical therapy, data from the firm-sponsored COMPANION study show
You may also be interested in...
Resynchronization Reduces Progressive Heart Failure Death By 51% – Study
Inclusion of COMPANION trial data in a future meta-analysis could confirm a beneficial effect of cardiac resynchronization on total mortality, Sergio Pinski, MD, Cleveland Clinic Florida, speculates in an editorial published in the Feb. 12 Journal of the American Medical Association
Resynchronization Reduces Progressive Heart Failure Death By 51% – Study
Inclusion of COMPANION trial data in a future meta-analysis could confirm a beneficial effect of cardiac resynchronization on total mortality, Sergio Pinski, MD, Cleveland Clinic Florida, speculates in an editorial published in the Feb. 12 Journal of the American Medical Association
Guidant Boosts CHF Resynchronization Therapy R&D With VivoMetrics Deal
Guidant looks to use VivoMetrics' LifeShirt ambulatory monitoring system in an upcoming congestive heart failure registry after reaching a purchasing agreement with the firm Dec. 4